ArticleAntiviral research2020
Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening.
Article in Antiviral research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 46 citations in OpenAlex.
- Neuronal Apoptotic Bodies Facilitate Japanese Encephalitis Virus Infection and Pathogenicity.Journal of extracellular vesicles · 2026Article
- Investigating the therapeutic potential of the antibacterial drug nitroxoline in combating cryptococcal infection.PLoS neglected tropical diseases · 2026Article
- Japanese encephalitis virus hijacks the host purine biosynthetic network to promote viral replication in neurons.PLoS pathogens · 2026Article
- Article
- Antimycin A inhibits alpha-herpesvirus replication by disrupting the formation of pyrimidinosomes.Journal of advanced research · 2026Article
- Universal and quantitative detection of double-stranded RNAs as a signature of pan-virus infections using a luciferase-based biosensor.Journal of biological engineering · 2025Article
- Three-dimensional mapping of tick-borne encephalitis virus distribution in the mouse brain using a newly engineered TurboGFP reporter virus.Emerging microbes & infections · 2025Article
- Article
- Uncovering nitroxoline activity spectrum, mode of action and resistance across Gram-negative bacteria.Nature communications · 2025Article
- Development of a HiBiT-tagged reporter Akabane virus and its application in antiviral drug screening.Frontiers in cellular and infection microbiology · 2025Article
- Reporter-expressing viruses for antiviral drug discovery research.Frontiers in cellular and infection microbiology · 2025Review
- Article
- Combinatory Effect of Nitroxoline and Gentamicin in the Control of Uropathogenic Enterococci Infections.Antibiotics (Basel, Switzerland) · 2024Article
- Engineering recombinant replication-competent bluetongue viruses expressing reporter genes forMicrobiology spectrum · 2024Article
- Screening for anti-influenza virus compounds from traditional Mongolian medicine by GFP-based reporter virus.Frontiers in cellular and infection microbiology · 2024Article
- Repurposing of Nitroxoline as an Alternative Primary Amoebic Meningoencephalitis Treatment.Antibiotics (Basel, Switzerland) · 2023Article
- A high throughput antiviral screening platform for alphaviruses based on Semliki Forest virus expressing eGFP reporter gene.Virologica Sinica · 2023Article
- Peripheral Nerve Injury Induced by Japanese Encephalitis Virus in C57BL/6 Mouse.Journal of virology · 2023Article
- Review
- Pinostrobin from plants and propolis against human coronavirus HCoV-OC43 by modulating host AHR/CYP1A1 pathway and lipid metabolism.Antiviral research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Japanese encephalitis virus (JEV), a major cause of Japanese encephalitisis, is an arbovirus that belongs to the genus Flavivirus of the family Flaviviridae. Currently, there is no effective drugs available for the treatment of JEV infection. Therefore, it is important to establish efficient antiviral screening system for the development of antiviral drugs. In this study, we constructed a full-length infectious clone of eGFP-JEV reporter virus by inserting the eGFP gene into the capsid-coding region of the viral genome. The reporter virus RNA transfected-BHK-21 cells generated robust eGFP fluorescence signals that were correlated well with viral replication. The reporter virus displayed growth kinetics similar to wild type (WT) virus although replicated a little slower. Using a known JEV inhibitor, NITD008, we demonstrated that the reporter virus could be used to identify inhibitors against JEV. Furthermore, an eGFP-JEV-based high throughput screening (HTS) assay was established in a 96-well format and used for screening of 1443 FDA-approved drugs. Sixteen hit drugs were identified to be active against JEV. Among them, five compounds which are lonafarnib, cetylpyridinium chlorid, cetrimonium bromide, nitroxoline and hexachlorophene, are newly discovered inhibitors of JEV, providing potential new therapies for treatment of JEV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.